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Abstract
Background: Premenstrual syndrome (PMS) encompasses a wide variety of cyclic and recurrent physical, emotional, and
behavioral symptoms occurring during the late luteal phase of the menstrual cycle and abating shortly following the beginning of
menses. Although PMS is widely recognized, its etiopathogenesis is not yet understood. The present study investigates whether
the activity of the autonomic nervous system, which plays a vital role in orchestrating physiological homeostasis within the
human body, is altered during the menstrual cycle of women with different degrees of premenstrual symptomatology.
Methods: Sixty-two women in their 20s to 40s with regular menstrual cycles participated in this study. All subjects were
examined during the follicular and late luteal phases. Cycle phase was determined by the onset of menstruation and oral
temperature and was verified by concentrations of ovarian hormones, estrone, and pregnanediol in a urine sample taken early
in the morning. Autonomic nervous system activity was assessed by means of heart-rate variability (HRV) power spectral analysis
during supine rest. The Menstrual Distress Questionnaire was used to evaluate physical, emotional, and behavioral symptoms
accompanying the menstrual cycle of the subjects. The subjects were categorized in three groups, Control, PMS, and
premenstrual dysphoric disorder (PMDD) groups, depending on the severity of premenstrual symptomatology.
Results: No intramenstrual cycle difference in any of the parameters of HRV was found in the Control group, which had no or
a small increase in premenstrual symptoms. In contrast, Total power and high frequency  power, which reflect overall autonomic
and parasympathetic nerve activity, respectively, significantly decreased in the late luteal phase from the follicular phase in the
PMS group. As for the PMDD group, which had more severe symptoms premenstrually, heart-rate fluctuation as well as all
components of the power spectrum of HRV were markedly decreased regardless of the menstrual cycle compared to those of
the other two groups.
Conclusion: Several theories have been proposed to explain the underlying mechanisms of PMS with its complex web of bio-
psycho-social factors. Although causes and consequences continue to elude, the present study provides intriguing and novel
findings that the altered functioning of the autonomic nervous system in the late luteal phase could be associated with diverse
psychosomatic and behavioral symptoms appearing premenstrually. In addition, when symptoms become more severe (as seen
in women with PMDD), the sympathovagal function might be more depressed regardless of the menstrual cycle.
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Background
Premenstrual syndrome (PMS) is characterized by the
cyclic nature of a collection of psychological, physiologi-
cal, and/or behavioral symptoms appearing during the
late luteal phase of the menstrual cycle and usually disap-
pearing shortly after the onset of menses [1,2]. Epidemio-
logical studies, including those in Japan, have shown that
up to 90% of women of childbearing age experience at
least some degree of premenstrual symptomatology, with
an estimated 3–8% having symptoms severe enough to
disrupt everyday life and/or interpersonal relationships
and to be classified as premenstrual dysphoric disorder
(PMDD) [3,4]. Furthermore, according to Kraemer and
Kraemer [5], 220 out of 492 women in their study have
doctor shopped, seeing an average 3.75 physicians over an
average 5.33 years before being diagnosed with PMS and/
or effectively treated to alleviate their symptoms.
Notwithstanding this high prevalence, no specific symp-
toms or signs appear, nor are any recognizable anatomical
factors identified in women suffering from PMS, and
hence, no universal treatment yet exists. Over the past 70
years, medical and psychological studies have proposed
many different theories on the etiology of the premen-
strual experience, such as estrogen excess, progesterone
deficiency, serotonergic abnormalities, and opioids with-
drawal [3,4]. However, the underlying mechanism of
PMS, which is multifactorial and might affect diverse neu-
ropsychophysiological systems, remains unclear and spec-
ulative.
Sympathetic and parasympathetic divisions of the auto-
nomic nervous system function antagonistically, comple-
mentarily, and/or harmoniously to play a crucial role in
dynamically controlling the response of the body to a
range of external and internal stimuli, maintaining nearly
every important homeostatic process in the body. Insta-
bility or even a slight disorder of the autonomic nervous
system, therefore, could induce broadly ranged psycho-
physiological phenomena, such as premenstrual symp-
tomatology, and ultimately, far-reaching adverse effects
on health. Despite findings that the autonomic function is
altered in people with psychosomatic symptoms such as
depression [6], anxiety [7], or chronic fatigue [8], a pau-
city of information exists regarding the potential associa-
tion of PMS and autonomic nervous system activity.
The electrocardiogram (ECG) sampling of R-R interval
variation, or inter-beat interval oscillation of the heart rate
is regulated by the net effect of sympathetic and parasym-
pathetic input. The spectral analysis of heart-rate variabil-
ity (HRV) has provided a comprehensive quantitative and
qualitative assessment of sympathetic and parasympa-
thetic components of the autonomic nervous system [9].
In addition, HRV power spectral analysis lightens the bur-
den imposed on subjects during an experiment, unlike
invasive measurements, i.e., plasma catecholamine con-
centration and muscle sympathetic nerve activity. This
method, already an established patient-friendly tool in
cardiology research, is increasingly used for a broad range
of clinical as well as psychophysiological applications [9-
13].
Accordingly, the present study evaluates resting auto-
nomic nervous system activity by means of HRV power
spectral analysis of eumenorrheic women with different
degrees of premenstrual symptoms – from molimina,
within the normal range of change, to PMDD, severe PMS
[14]. We investigated the extent to which and the manner
in which the menstrual cyclicity of autonomic nervous
system activity relates to a constellation of diverse symp-
toms appearing in the late luteal phase.
Methods
Subjects
Sixty-two women in their 20s to 40s with regular men-
strual cycles participated in this study. The study protocol
was approved in advance by the Institutional Review
Board of International Buddhist University and was per-
formed in accordance with the Declaration of Helsinki of
the World Medical Association. All subjects received an
explanation of the nature and purpose of the study, and
all gave their written informed consent to enter the study.
Prior to obtaining any data from experiments, the subjects
had medical examinations and interviews and completed
a standardized health questionnaire regarding medical
history, medications, current health condition, menstrual
cycle (length of cycle, length of menstrual flow, and regu-
larity of cycle), premenstrual discomfort, and lifestyle. All
subjects self-reported regular menstrual cycles for at least
two cycles. None of the subjects was clinically diagnosed
with diabetes mellitus, hypertension, cardiovascular dis-
ease, or any other endocrine or systemic disorders.
Experimental Procedure
All subjects were examined on two separate occasions:
once during the follicular phase (within five days after the
completion of menstrual bleeding), and once during the
late luteal phase (within seven days before the next men-
struation). The order of testing during the cycle was rand-
omized to guard against possible bias due to "learning"
effects so that equal numbers of subjects were studied first
in each phase. Cycle phase was determined by the onset of
menstruation and oral temperature and verified by con-
centrations of ovarian hormones in a urine sample taken
early in the morning [13].
All measurements in the follicular and late luteal phase
for subjects were taken between 9:00 and 15:00. The room
was temperature controlled at 25°C, quiet, and comforta-BioPsychoSocial Medicine 2007, 1:24 http://www.bpsmedicine.com/content/1/1/24
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ble, with minimization of arousal stimuli. Height and
body weight of each subject were measured to calculate
body mass index (BMI) as body weight divided by height
squared. After skin preparation, the subjects were fitted
with ECG electrodes. They then rested for at least 10 min-
utes before the start of the experiment. After the resting
period, the CM5 lead ECG was continuously recorded for
five minutes during supine rest. All subjects breathed in
synchrony to a metronome at 15 beats·min-1 (0.25 Hz) to
ensure that respiratory-linked variations in heart rate did
not overlap with lower-frequency heart-rate fluctuations
(below 0.15 Hz) from other sources. The ECG sampling of
R-R interval variations were later analyzed via HRV power
spectral analysis described above to evaluate autonomic
nervous system activity during the menstrual cycle.
After the subjects completed ECG measurement, each
filled out the Menstrual Distress Questionnaire (MDQ)
[15], which evaluated physical, emotional, and behavio-
ral symptoms accompanying the menstrual cycle. The
MDQ covers 46 symptoms in eight categories: pain, con-
centration, behavioral change, autonomic reactions, water
retention, negative affect, arousal, and control. The sub-
jects were asked to rate their experience relative to all 46
symptoms on the questionnaire on a six-point scale rang-
ing from no experience of the symptom to so extremely
severe as to cause disruption of daily activities.
R-R interval power spectral analysis procedure
Periodic components of HRV tend to aggregate within sev-
eral frequency bands [16-18]. The autonomic nervous sys-
tem activity was thus noninvasively measured by HRV
power spectral analysis, which decomposes the series of
sequential R-R intervals into a sum of sinusoidal functions
of different amplitudes and frequencies by the Fourier
transform algorithm. The technique of the analysis for the
present investigation has been applied in basic physiolog-
ical and clinical research fields, and its validity and relia-
bility has been previously confirmed [11-13,19-22]. The
procedure of R-R interval power spectral analysis used in
the present study has been described in great detail else-
where [19,20]. Briefly, the ECG signal was amplified
(MEG-6108, Nihon Kohden, Tokyo, Japan) and digitized
via a 16-bit analog-to-digital converter (Model PS-
2032GP, TEAC, Tokyo, Japan) at a sampling rate of 1000
Hz. The digitized ECG signal was differentiated, and the
resultant QRS spikes and the intervals of the impulses (R-
R intervals) were stored sequentially on a hard disk for
later analyses.
Before the R-R spectral analysis was performed, the stored
R-R interval data were displayed and aligned sequentially
to obtain equally spaced samples with an effective sam-
pling frequency of 2 Hz [23] and displayed on a computer
screen for visual inspection. Then, the direct current com-
ponent and linear trend were completely eliminated by
digital filtering for the band-pass between 0.03 and 0.5
Hz. The root mean square value of the R-R interval was
calculated as representing the average amplitude. After
passing through the Hamming window, power spectral
analysis by means of a fast Fourier transform was per-
formed on a consecutive 256-sec time series of R-R inter-
val data obtained during the test. Spectral powers were
calculated for the following respective frequency band:
low frequency (LF) power (0.03 and 0.15 Hz), an indica-
tor of both sympathetic and parasympathetic nervous sys-
tem activity; high frequency (HF) power (0.15 and 0.5
Hz), which solely reflects parasympathetic nerve activity;
and Total power (0.03 and 0.5 Hz) representing overall
ANS activity [11,12,19,20,22].
Urinary analysis
Each subject collected urine at the first urine void in the
morning. Refrigerated 10-mL aliquots of urine were
immediately frozen and stored at -20°C until assay. Urine
samples were then analyzed for estrone (E1) and pregnan-
ediol-3-glucuronide (PdG) by radioimmunoassay by
referring to Munro et al. [24] and De Souza et al. [25]. E1
and PdG were both indexed to creatinine (Cr) excretion in
the same sample to control for variations in urine volume.
E1 and PdG are expressed as nanograms and micrograms
per mg Cr, respectively.
Statistical analysis
All data are expressed as mean ± SE. Since most of the HRV
parameters were not normally distributed as Landen et al.
[26] formally suggested, Mann-Whitney U-test was used
for comparison between groups, and Wilcoxon Matched-
Pairs Signed-Ranks Test for within group comparisons. As
to the parameters of symptoms with menstrual cycles and
other clinical features, ANOVA using post hoc Tukey's test
was used for comparisons between groups, and paired t-
test for within group comparisons. P values < 0.05 were
considered statistically significant. All statistical analysis
was performed using a commercial software package
(SPSS version 13.0 for Windows, SPSS, Inc., Illinois).
Results
Clinical characteristics of subjects
Mean values of physical features of all subjects were as fol-
lows: age 26.9 ± 1.0 years, height 160.0 ± 0.6 cm, weight
54.8 ± 0.6 kg, and BMI 21.4 ± 0.2 kg/m2. Length of men-
strual cycle and duration of menstrual flow of subjects
during the study were 30.8 ± 0.5 days and 6.3 ± 0.1 days,
respectively. The experiments took place on the 8.3 ±
0.3th day in the follicular phase and 28.0 ± 0.6th day in
the late luteal phase from the first day of menstruation.
Concerning menstrual cycle symptomatology, some sub-
jects had apparent physical and psychological discomfortBioPsychoSocial Medicine 2007, 1:24 http://www.bpsmedicine.com/content/1/1/24
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in the late luteal phase, while others experienced few
symptoms. To scrutinize the potential influence of pre-
menstrual discomfort on autonomic nervous system
activity, we first categorized the subjects into two groups
based on the increase in scores on the MDQ from the fol-
licular to the late luteal phase while referring to the find-
ings from our recent study [13], i.e., 28 subjects in the
Control group (less than 20%) and 23 subjects in the PMS
group (greater than 20%). None of the subjects in the
PMS group had disruption of normal activities due to pre-
menstrual symptomatology. The remaining 11 subjects,
however, experienced distressing psychophysiological
and behavioral changes of sufficient severity to result in
deterioration of interpersonal relationships and/or inter-
ference with daily and/or social activities. They sought
medical treatment, according to the results of medical
consultation and the MDQ scores. The 11 subjects also
met the criteria for PMDD according to the Diagnostic
and Statistical Manual of Mental Disorders IV (DSM-IV)
[27]. They were, thus, categorized in the PMDD group.
The mean values and range of age in the Control, PMS,
and PMDD groups were 25.3 ± 1.3 (20 – 47), 26.7 ± 1.8
(20 – 43), and 31.2 ± 1.9(22 – 43) years, respectively, with
no significant difference among the three groups. As to
clinical characteristics shown in Table 1, concentration of
E1 and PdG in urine was elevated from the follicular to
the late luteal phase in all three groups. Group compari-
son revealed no significant difference in ovarian hor-
mones or in body composition during the menstrual cycle
among the three groups.
Bio-psycho-behavioral symptoms
Figure 1 represents MDQ scores in the follicular and the
late luteal phases in all three groups. No significant
increase was detected in total scores between the men-
strual phases in the Control group. In the PMS and PMDD
groups, in contrast, total scores of MDQ in the late luteal
phase markedly increased compared to those in the follic-
ular phase (p < 0.01). The increase in the MDQ scores
from the follicular to the late luteal phase was greater in
the PMDD group (61.9 ± 11.8%) than in the PMS group
(36.2 ± 3.9%). Scores of all eight factors of MDQ also
increased from the follicular to the late luteal phase in the
PMS and PMDD groups. The most remarkable change
between menstrual phases was detected in negative affect
(137.3 ± 36.8%), followed by the scores of behavioral
change (93.9 ± 29.1%) and water retention (71.8 ±
13.5%), within the PMDD group. As to the PMS group,
subscores of concentration (49.8 ± 9.6%) and negative
affect (47.8 ± 8.3%) increased more apparently compared
to the other factors.
Group comparison revealed significant differences in total
scores on the MDQ in the late luteal phase among the
three groups (p < 0.01); the scores of the PMS group (74.5
± 2.4) and PMDD group (106.3 ± 9.5) were approxi-
mately 1.5 and 2.1 times greater than that of the Control
group (50.3 ± 0.6), respectively. The PMDD group pos-
sessed higher scores even in the follicular phase compared
to the Control group (66.8 ± 5.9 vs. 50.3 ± 0.7, p < 0.01).
Autonomic nervous system activity
Figure 2 represents typical sets of raw R-R interval and the
corresponding power spectral data obtained from subjects
in the Control, PMS, and PMDD groups. We observed
widely fluctuated R-R interval and corresponding power
spectrum without intramenstrual cycle differences in the
Control group subjects. As to the subjects in the PMS
group, the HF component of the power spectrum as well
as the R-R interval variability decreased in the sympto-
matic late luteal phase compared to that of the follicular
phase. The degree of R-R interval fluctuation and corre-
sponding power spectrum in the follicular phase did not
seem to differ between the subjects in the Control and
PMS groups. In contrast, the most severe cases we
observed among subjects in the PMDD group demon-
strate the range of R-R interval variability and spectral
power were more markedly reduced regardless of men-
strual cycle, compared to the subjects in the Control and
PMS groups.
As shown in Figure 3, statistical procedures revealed no
differences in any parameters of HRV between the follicu-
Table 1: Clinical characteristics of subjects in the follicular and late luteal phase
Control group (n = 28) PMS group (n = 23) PMDD group (n = 11)
Follicular Luteal Follicular Luteal Follicular Luteal
Estrone (ng/ml Cr) 10.7 ± 1.0 19.4 ± 2.2** 10.9 ± 1.4 19.3 ± 2.5** 11.3 ± 2.8 21.7 ± 3.5*
Pregnanediol-3-glucuronide (μg/ml Cr) 0.4 ± 0.04 2.1 ± 0.19** 0.3 ± 0.04 2.2 ± 0.3** 0.8 ± 0.4 2.1 ± 0.4
Weight (kg) 54.7 ± 1.2 55.0 ± 1.3 55.9 ± 1.6 56.0 ± 1.6 51.8 ± 2.4 52.6 ± 2.4
Body Mass Index (kg/m2) 21.9 ± 0.5 22.0 ± 0.5 21.1 ± 0.5 21.2 ± 0.5 20.5 ± 0.9 20.8 ± 0.9
Cr: creatinine
Values are means ± SE. **p < 0.01; *p < 0.05 (follicular phase vs. late luteal phase)BioPsychoSocial Medicine 2007, 1:24 http://www.bpsmedicine.com/content/1/1/24
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lar and late luteal phase in the Control group. In the PMS
group, however, Total power (p < 0.05) and the HF com-
ponent of the power spectrum (p < 0.05) were signifi-
cantly lower in the symptomatic late luteal phase than in
the follicular phase. LF power did not significantly change
from the follicular to the late luteal phase in the PMS
group. As for the PMDD group, we found obvious reduc-
tion in all the power spectral components of HRV in both
menstrual phases compared to the other two groups (p <
0.05). No intramenstrual cycle difference in any of the
components of power was detected in the PMDD group.
Discussion
PMS comprises myriad nonspecific physical, emotional,
behavioral, and cognitive symptoms that occur in the days
prior to menstruation and is nearly omnipresent in
women of reproductive age from all cultures and socioe-
conomic levels. The most prevalent symptoms include:
irritability, mood lability, depression, anxiety, impulsiv-
ity, feelings of "loss of control," fatigue, decreased concen-
tration, abdominal bloating, fluid retention, breast
swelling, and general aches [1-4,14]. Although PMS has a
multicausal origin and its etiopathogenesis is not yet
understood, it is conceivable that altered function of the
autonomic nervous system, which largely contributes to
the relative stability of a human's internal environment, is
associated with the cluster of symptoms appearing pre-
menstrually. The severity and frequency of symptoms
experienced may differ between women. The nature of the
premenstrual experience is usually stable within each
woman but may also fluctuate between her menstrual
cycles. This could be attributed to inter-intra individual
variability in the change in many aspects of homeostatic
functionality during the menstrual cycle [2].
HRV measurements are increasingly used in applications
ranging from basic investigations and central regulation
of autonomic state to studies of fundamental links
between psychological processes and physiological func-
tions and evaluations of cognitive development and clin-
ical risk [9]. According to Kim et al. [28], as an ancillary
study of the Women's Health Initiative Observational
Study, women with symptoms of depression had signifi-
cant reductions in HRV and higher heart rate, suggestive of
increased sympathetic tone. Yeragani [29], using HRV
power spectral analysis, have shown that both Total
power and HF power markedly decreased in female
patients with depression. Our recent study [22] with this
method has revealed that patients with climacteric disor-
ders possessed altered sympathovagal balance. After
patient-oriented humanistic psychotherapy, however,
unidentified symptoms ameliorated while autonomic
imbalance improved with the predominance of parasym-
pathetic nerve activity. These findings demonstrated that
power spectral analysis of HRV not only can evaluate the
activities of both branches of the autonomic nervous sys-
tem but also have potential capacity to scrutinize an intri-
cate relationship between psycho-behavioral and
physiological processes.
With this bio-fluctuomatics technology, the present study
provides intriguing and novel information regarding
autonomic nervous system activity during the menstrual
cycle in women with different degrees of premenstrual
symptomatology. The main findings indicate that no
intramenstrual cycle differences in any parameters of HRV
were found in the Control group experiencing no or small
increases in premenstrual symptoms. It should be men-
tioned that the widely fluctuated R-R interval and the cor-
responding power spectrum in the Control group shown
in Figure 2 were frequently observed in healthy individu-
als in our previous research [11,19-21]. In the PMS group,
however, Total power and HF power were significantly
decreased in the late luteal phase from the follicular
phase. As to the PMDD group suffering more severe nega-
tive emotional symptoms, heart-rate fluctuation as well as
all components of the power spectrum were markedly
more reduced regardless of the menstrual cycle compared
to the other two groups. Although estrogens and proges-
terone cannot be excluded as etiological factors of PMS,
no significant correlation was detected between urinary
ovarian hormone concentration, sympathovagal activity,
and premenstrual symptomatology. In addition, age is an
important factor influencing autonomic nervous system
activity [22,30], but no significant difference was found
among the three groups in the present study. Whether the
autonomic changes are primary or secondary could not be
Comparison of scores on the menstrual distress question- naire (MDQ) between the follicular and late luteal phases in  the Control, PMS, and PMDD groups Figure 1
Comparison of scores on the menstrual distress question-
naire (MDQ) between the follicular and late luteal phases in 
the Control, PMS, and PMDD groups. Results are expressed 
as mean ± SE. for each group. ** p < 0.01BioPsychoSocial Medicine 2007, 1:24 http://www.bpsmedicine.com/content/1/1/24
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discerned based on evidence presently available. This
study, however, indicates that parasympathetic nervous
system activity decreased in the symptomatic late luteal
phase compared to the follicular phase in women who
experienced a substantial increase (> 20%) in diverse, but
not unbearable, psychosomatic symptoms premen-
strually. The study also suggests that physiological func-
tion in both branches of the autonomic nervous system
might be more depressed during the entire menstrual
cycle when premenstrual symptoms become more severe
as seen in women suffering from PMDD.
We have extensively reviewed the literature regarding the
physiological role of the autonomic nervous system in
premenstrual symptomatology. Kondo et al. [31] meas-
ured the coefficient of variation of R-R interval during the
Examples of ECG R-R interval changes and the corresponding power spectra during the follicular and late luteal phase for sub- jects in the Control, PMS, and PMDD groups Figure 2
Examples of ECG R-R interval changes and the corresponding power spectra during the follicular and late luteal phase for sub-
jects in the Control, PMS, and PMDD groups. LF: low frequency power (0.03–0.15 Hz); HF: high frequency power (0.15–0.5 
Hz).BioPsychoSocial Medicine 2007, 1:24 http://www.bpsmedicine.com/content/1/1/24
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menstrual cycle and demonstrated that the parasympa-
thetic nerve activity was lower in the late luteal phase than
in the follicular phase in women with PMS. A recent clin-
ical study by Kimura et al. [32] has applied noninvasive
pulse wave analysis to assess the peripheral autonomic
reaction as well as arterial elasticity properties and sug-
gested that Kampo therapy could induce vascular rejuve-
nation, an indication of improvement of autonomic
nervous disturbance in PMS patients, while significantly
improving premenstrual discomfort. We have utilized the
venous oxygenation index (VOI) via the principle of near-
infrared spectroscopy to evaluate peripheral blood circu-
lation and demonstrated that the VOI significantly
decreased in women with PMS [33]. This result implies
altered circulation – at least partly ascribed to autonomic
imbalance – is associated with premenstrual symptoms.
Although in limited numbers, an association of the auto-
nomic function and PMDD has also been investigated.
Girdler et al. [34] revealed that women with PMDD had
significantly elevated norepinephrine and total peripheral
resistance at rest and during mental stressors compared
with control subjects. These phenomena occurred in both
the follicular and luteal phases. Recent research by Landen
et al. [26] with time and frequency domain of HRV meas-
urement has shown an interesting finding, which suggests
that women with PMDD have reduced vagal tone com-
pared to controls and that this difference is more apparent
in the non-symptomatic follicular phase.
Despite the differences in experimental designs and con-
ditions as well as an index of the autonomic nervous sys-
tem, these earlier investigations [26,31-34] support our
findings, indicating that the occurrence of premenstrual
symptomatology could be attributable to an altered func-
tioning of the autonomic nervous system in the sympto-
matic late luteal phase. The findings of PMDD from the
present study together with Landen et al. [26] and Girdler
et al. [34] indicate sympathovagal activity was altered
even in the follicular phase. Does this imply that women
with lower autonomic function regardless of the men-
strual cycle are vulnerable to more severe premenstrual
disorders? Clinical research on the menstrual cycle has
been conducted from various perspectives, and several
theoretical models, such as estrogen excess, progesterone
deficiency, decreases in serotonergic tone, alteration of
central GABA function, and opioids withdrawal, have
been proposed as the pathogenesis of PMS [3,4,14]. How-
ever, at the moment, the underlying biomechanisms of
PMS remain enigmatic. Future multidirectional and inter-
disciplinary approaches will be needed to confirm an eti-
ological association of premenstrual symptomatology
with the complex web of bio-psycho-social factors around
the menstrual cyclicity of sympathovagal function.
Conclusion
According to Mishell [3], women have approximately 481
menstrual cycles during their childbearing years. With an
average adjustment of 22 months for two pregnancies and
postpartum periods, they would actually experience about
459 cycles. Regular menstrual cycles could offer an index
of women's reproductive health. A majority of women,
however, experience "a cacophony of mind and body" in
the late luteal phase, that is, premenstrual symptomatol-
ogy. The present study attempted to investigate these peri-
odical psychophysiological phenomena from the
perspective of autonomic nervous system activity with
HRV power spectral analysis. Although the underlying
pathophysiological mechanisms remain unclear, the
present study suggests that altered functioning of the auto-
nomic nervous system in the late luteal phase could be
associated with diverse psychosomatic and behavioral
symptoms appearing premenstrually. In addition, when
the symptoms become more severe, as seen in women
with PMDD, the sympathovagal function might be more
depressed regardless of the menstrual cycle.
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